atazanavir sulfate has been researched along with Metabolic Syndrome in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nzuza, S; Owira, PMO; Zondi, S | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Furrer, H; Glass, TR; Hirschel, B; Rickenbach, M; Tarr, PE; Vernazza, P; Young, J | 1 |
| Bernal, E; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Padilla, S; Ramos, JM | 1 |
| Bain, AM; Bedimo, R; Busti, AJ; Eaton, SA; Herrington, JD; Maclayton, DO; Nguyen, ST; Payne, KD; Rahman, AP; Rodriguez-Barradas, MC | 1 |
4 other study(ies) available for atazanavir sulfate and Metabolic Syndrome
| Article | Year |
|---|---|
Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Atazanavir Sulfate; Blood Glucose; Body Weight; Caspase 3; Caspase 9; Drinking; Fasting; Flavanones; Glucokinase; Glucose Intolerance; HIV Protease; HIV Protease Inhibitors; Homeostasis; Insulin; Insulin Resistance; Liver; Male; Metabolic Syndrome; Pancreas; Rats, Wistar; Saquinavir; Signal Transduction; Uncoupling Protein 2 | 2017 |
Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Metabolic Syndrome; Models, Statistical; Oligopeptides; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Switzerland | 2009 |
[Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors | 2007 |
Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Mass Index; Body Weight; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir | 2008 |